Busey Bank Has $16.63 Million Stock Holdings in AbbVie Inc. $ABBV

Posted by Geri Gentry on Jul 6th, 2026

Busey Bank trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 76,483 shares of the company’s stock after selling 2,446 shares during the quarter. Busey Bank’s holdings in AbbVie were worth $16,634,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $5,865,055,000. Wellington Management Group LLP raised its holdings in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Capital World Investors raised its holdings in shares of AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares during the period. Cardano Risk Management B.V. lifted its position in AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

AbbVie stock opened at $260.88 on Monday. AbbVie Inc. has a 52 week low of $184.63 and a 52 week high of $261.64. The stock has a 50-day simple moving average of $220.19 and a 200 day simple moving average of $220.25. The stock has a market capitalization of $460.92 billion, a P/E ratio of 128.51, a PEG ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the business earned $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Research analysts forecast that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. Cantor Fitzgerald reiterated an “overweight” rating on shares of AbbVie in a report on Tuesday, June 23rd. Wells Fargo & Company set a $260.00 price objective on AbbVie in a research report on Monday, June 22nd. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Finally, Canaccord Genuity Group boosted their target price on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.81.

Check Out Our Latest Research Report on AbbVie

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.